Korro Bio (KRRO) Stock Forecast & Price Target

Compare

557 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

KRRO Analyst Ratings

Moderate Buy

5 Buy

5 Hold

0 Sell

Based on 10 analysts giving stock ratings to

Korro

Bio

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

KRRO Stock 12 Month Forecast

Average Price Target

$18.00

▲(35.24% Upside)

Based on 10 Wall Street analysts offering 12 month price targets for Korro Bio in the last 3 months. The average price target is $18.00 with a high forecast of $30.00 and a low forecast of $8.00. The average price target represents a 35.24% change from the last price of $13.31.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","14":"$14","24":"$24","34":"$34","44":"$44"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":30,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$30.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":18,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$18.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":8,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$8.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,14,24,34,44],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Apr<br/>2025","6":"Jul<br/>2025","9":"Oct<br/>2025","12":"Jan<br/>2026","25":"Jan<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.01,9.701538461538462,11.393076923076922,13.084615384615384,14.776153846153846,16.46769230769231,18.159230769230767,19.85076923076923,21.542307692307695,23.233846153846155,24.925384615384615,26.61692307692308,28.308461538461536,{"y":30,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.01,8.778461538461539,9.546923076923077,10.315384615384616,11.083846153846153,11.852307692307694,12.62076923076923,13.38923076923077,14.157692307692308,14.926153846153847,15.694615384615386,16.463076923076926,17.231538461538463,{"y":18,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.01,8.009230769230768,8.008461538461539,8.007692307692308,8.006923076923076,8.006153846153847,8.005384615384616,8.004615384615384,8.003846153846153,8.003076923076923,8.002307692307692,8.00153846153846,8.000769230769231,{"y":8,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":38.07,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.12,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.07,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.95,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.4,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.8,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.77,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.85,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.2,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.9,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":40.91,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.01,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$30.00

Average Price Target$18.00

Lowest Price Target$8.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Yasmeen Rahimi

Piper Sandler

$30

Buy

125.39%

Upside

Upgraded

01/29/26

Korro Bio upgraded to Overweight from Neutral at Piper SandlerKorro Bio upgraded to Overweight from Neutral at Piper Sandler

Mitchell Kapoor

H.C. Wainwright

$20

Buy

50.26%

Upside

Upgraded

01/29/26

Korro Bio upgraded to Buy from Neutral at H.C. WainwrightKorro Bio upgraded to Buy from Neutral at H.C. Wainwright

Myles Minter

William Blair

Hold

―

Reiterated

01/28/26

Analysts Conflicted on These Healthcare Names: Korro Bio (NASDAQ: KRRO), Kazia Therapeutics (NASDAQ: KZIA) and AbbVie (NYSE: ABBV)

Kostas Biliouris

Oppenheimer

$22

Buy

65.29%

Upside

Upgraded

01/28/26

Korro Bio upgraded to Outperform from Perform at OppenheimerKorro Bio upgraded to Outperform from Perform at Oppenheimer

William Maughan

Clear Street

$7→$10

Hold

-24.87%

Downside

Reiterated

01/27/26

Korro Bio price target raised to $10 from $7 at Clear StreetKorro Bio price target raised to $10 from $7 at Clear Street

Steven Seedhouse

Cantor Fitzgerald

$81→$21

Buy

57.78%

Upside

Upgraded

01/27/26

Korro Bio upgraded to Overweight from Neutral at Cantor FitzgeraldKorro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald

Keay Nakae

Chardan Capital

$7→$15

Buy

12.70%

Upside

Upgraded

01/27/26

Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Pfizer (NYSE: PFE) and Alpha Teknova (NASDAQ: TKNO)

Catherine Novack

JonesTrading

Hold

―

Downgraded

11/13/25

Korro Bio's Strategic Shift Amidst Clinical Setbacks and Financial Stability Justifies Hold Rating

Ryan Deschner

Raymond James

Hold

―

Downgraded

11/13/25

Raymond James downgrades Korro Bio (KRRO) to a Hold

Luca Issi

RBC Capital

$85→$8

Hold

-39.89%

Downside

Downgraded

11/13/25

RBC Capital downgrades Korro Bio (KRRO) to a Hold

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Yasmeen Rahimi

Piper Sandler

$30

Buy

125.39%

Upside

Upgraded

01/29/26

Korro Bio upgraded to Overweight from Neutral at Piper SandlerKorro Bio upgraded to Overweight from Neutral at Piper Sandler

Mitchell Kapoor

H.C. Wainwright

$20

Buy

50.26%

Upside

Upgraded

01/29/26

Korro Bio upgraded to Buy from Neutral at H.C. WainwrightKorro Bio upgraded to Buy from Neutral at H.C. Wainwright

Myles Minter

William Blair

Hold

―

Reiterated

01/28/26

Analysts Conflicted on These Healthcare Names: Korro Bio (NASDAQ: KRRO), Kazia Therapeutics (NASDAQ: KZIA) and AbbVie (NYSE: ABBV)

Kostas Biliouris

Oppenheimer

$22

Buy

65.29%

Upside

Upgraded

01/28/26

Korro Bio upgraded to Outperform from Perform at OppenheimerKorro Bio upgraded to Outperform from Perform at Oppenheimer

William Maughan

Clear Street

$7→$10

Hold

-24.87%

Downside

Reiterated

01/27/26

Korro Bio price target raised to $10 from $7 at Clear StreetKorro Bio price target raised to $10 from $7 at Clear Street

Steven Seedhouse

Cantor Fitzgerald

$81→$21

Buy

57.78%

Upside

Upgraded

01/27/26

Korro Bio upgraded to Overweight from Neutral at Cantor FitzgeraldKorro Bio upgraded to Overweight from Neutral at Cantor Fitzgerald

Keay Nakae

Chardan Capital

$7→$15

Buy

12.70%

Upside

Upgraded

01/27/26

Analysts Offer Insights on Healthcare Companies: Korro Bio (NASDAQ: KRRO), Pfizer (NYSE: PFE) and Alpha Teknova (NASDAQ: TKNO)

Catherine Novack

JonesTrading

Hold

―

Downgraded

11/13/25

Korro Bio's Strategic Shift Amidst Clinical Setbacks and Financial Stability Justifies Hold Rating

Ryan Deschner

Raymond James

Hold

―

Downgraded

11/13/25

Raymond James downgrades Korro Bio (KRRO) to a Hold

Luca Issi

RBC Capital

$85→$8

Hold

-39.89%

Downside

Downgraded

11/13/25

RBC Capital downgrades Korro Bio (KRRO) to a Hold

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Korro Bio

3 Months

xxx

Success Rate

8/14 ratings generated profit

Average Return

+9.13%

upgraded a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 57.14% of your transactions generating a profit, with an average return of +9.13% per trade.

1 Year

Kostas BiliourisOppenheimer

Success Rate

6/14 ratings generated profit

Average Return

+11.55%

upgraded a buy rating 3 days ago

Copying Kostas Biliouris's trades and holding each position for 1 Year would result in 42.86% of your transactions generating a profit, with an average return of +11.55% per trade.

2 Years

xxx

Success Rate

7/14 ratings generated profit

Average Return

+28.00%

upgraded a xxx

rating 3 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 50.00% of your transactions generating a profit, with an average return of +28.00% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

KRRO Analyst Recommendation Trends

Rating

Sep 25

Oct 25

Nov 25

Dec 25

Jan 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, KRRO has received 5 Buy Ratings, 10 Hold Ratings, and 0 Sell Ratings. KRRO average Analyst price target in the past 3 months is 18.00.

Each month's total comprises the sum of three months' worth of ratings.

KRRO Financial Forecast

KRRO Earnings Forecast

Next quarter’s earnings estimate for KRRO is -$2.07 with a range of -$3.19 to -$1.44. The previous quarter’s EPS was -$1.92. KRRO beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.25% of the time in the same period. In the last calendar year KRRO has Performed in-line its overall industry.

KRRO Sales Forecast

Next quarter’s sales forecast for KRRO is $670.00K with a range of $0.00 to $2.00M. The previous quarter’s sales results were $1.09M. KRRO beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.18% of the time in the same period. In the last calendar year KRRO has Performed in-line its overall industry.

KRRO Stock Forecast FAQ

What is KRRO’s average 12-month price target, according to analysts?

Based on analyst ratings, Korro Bio’s 12-month average price target is 18.00.

What is KRRO’s upside potential, based on the analysts’ average price target?

Korro Bio has 35.24% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is KRRO a Buy, Sell or Hold?

Korro Bio has a consensus rating of Moderate Buy which is based on 5 buy ratings, 5 hold ratings and 0 sell ratings.

What is Korro Bio’s price target?

The average price target for Korro Bio is 18.00. This is based on 10 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $30.00 ,the lowest forecast is $8.00. The average price target represents 35.24% Increase from the current price of $13.31.

What do analysts say about Korro Bio?

Korro Bio’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 10 Wall Streets Analysts.

How can I buy shares of KRRO?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Korro Bio (KRRO) Stock Forecast & Price Target

KRRO Analyst Ratings

KRRO Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Korro Bio

KRRO Analyst Recommendation Trends

KRRO Financial Forecast

KRRO Earnings Forecast

KRRO Sales Forecast

KRRO Stock Forecast FAQ

Detailed List of Analyst Forecasts